462 Studies Now Enrolling
A Phase 1b/2 study to assess the safety, tolerability and efficacy of BGB-290 in combination with radiation therapy and/or temozolomide in subjects with first-line or recurrent/refractory glioblastoma
Study of Drug BGB-290 in Patients with Glioblastoma
| Sponsor: | BeiGene, Ltd. |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAR6842 |
| U.S. Govt. ID: | NCT03150862 |
| Contact: | Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
Additional Study Information:
The purpose of this study is to look at the effects of an investigational anti-cancer drug (BGB-290) in combination with radiation therapy and/or temozolomide in patients with newly diagnosed or recurring glioblastoma. BGB-290 is expected to work by preventing cancer cells from repairing their damaged genes, causing the progression of cancer to slow down.
This study is closed
Do You Qualify?
| Are you 18 years or older? | Yes | No |
| Do you have a diagnosis of glioblastoma? | Yes | No |
| If you were recently diagnosed with glioblastoma, have you received treatment for your glioblastoma other than surgery? | Yes | No |
| If your glioblastoma has recently recurred, have you only received chemotherapy treatment with temozolomide? | Yes | No |